ROCKET PHARMACEUTICALS INC RCKT
ASignal's systematic analysis rates RCKT as Bearish.
Reflects the latest available analysis · analyzed Oct 11, 2026
The case on RCKT
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong cash position with $283.75M cash on balance sheet
- Low debt-to-equity ratio of 0.07x indicating conservative capital structure
- High current and quick ratios (9.24x, 9.06x) signaling strong liquidity
- RSI at 24.28 suggesting potential oversold condition
- Negative operating cash flow of $-170.27M
- Negative return on equity (-4.77%) and return on assets (-28.42%)
- Negative EV/EBITDA of -0.16x and unprofitable margins
- Declining price momentum and trading below key moving averages (SMA20, SMA50)
- Low Reddit retail interest with only 1 mention
- Limited news coverage from only three sources
See the full verdict on RCKT
ASignal Rank (1-4), confidence score, Value / Activist / Macro grades, price targets, and the full reasoning behind the call.
How ASignal analyzes RCKT
Most investors never get a second opinion, let alone several. ASignal runs RCKT past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: value discipline, activist catalysts, and macro analysis. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.